6 Health Care Stocks to Gain on Earnings
5. Cepheid (CPHD) a molecular diagnostics company, engages in developing, manufacturing and marketing fully-integrated systems for testing in the clinical market, as well as for application in legacy industrial, biothreat and partner markets. Cepheid will report its second quarter 2011 results on July 21 after market.
Analysts polled by Bloomberg expect Cepheid to record sales of $60.94 million for the second quarter of 2011 compared to $49.64 million in same quarter prior year. Net loss for the quarter is seen narrowing to $0.26 million, or 2-cents per share, from $1.80 million, or 3 cents per share, in the second quarter of 2010. Gross margin for the quarter is likely to expand to 55.53% from 49.21% in year ago period. EBITDA for the second quarter is seen rising by 34% to $2.1 million.
Of the 19 analysts covering the stock, 47% suggest a buy and the remaining rate a hold. There are no sell ratings on the stock. Analysts polled by Bloomberg foresee the stock gaining an average 3.3% to $31.70 in the upcoming 12 months.
Select the service that is right for you!
COMPARE ALL SERVICESAction Alerts PLUS
TRY IT FREEJim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
Product Features:
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Dividend Stock Advisor
TRY IT FREENew! $49.95/yr
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Product Features:
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Stocks Under $10
TRY IT FREEDavid Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Product Features:
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
- Weekly roundups
Real Money
TRY IT FREE24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.
Product Features:
- Jim Cramer + 20 Wall Street pros
- Intraday commentary & news
- Real-time trading forum
- Actionable trade ideas
Real Money Pro
TRY IT FREEAll of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Product Features:
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Options Profits
TRY IT FREEOur options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
Product Features:
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV
